Circulating tumour cell-derived plastin3 is a novel marker for predicting long-term prognosis in patients with breast cancer

H. Ueo, K. Sugimachi, T. M. Gorges, K. Bartkowiak, T. Yokobori, V. Müller, Y. Shinden, M. Ueda, H. Ueo, M. Mori, H. Kuwano, Y. Maehara, S. Ohno, K. Pantel, K. Mimori

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Background:Identification of promising biomarkers that predict the prognosis of patients with breast cancer is needed. In this study, we hypothesised that the expression of the epithelial-mesenchymal transition-related biomarker plastin3 (PLS3) in peripheral blood could be a prognostic factor in breast cancer.Methods:We examined PLS3 expression in breast cancer cell lines with epithelial and mesenchymal traits and in circulating tumour cells (CTCs) obtained from the peripheral blood of breast cancer patients. We investigated PLS3 expression in the peripheral blood of 594 patients with breast cancer to evaluate the clinical significance of PLS3 expression.Results:Robust PLS3 expression was observed in different breast cancer cell lines (Hs578t, MCF-7, MDA-MB-468, and MDA-MB-231) as well as in a bone marrow derived cancer cell line (BC-M1). In both the training (n=298) and validation (n=296) sets, PLS3 expression was observed in CTCs of patients with breast cancer. PLS3-positive patients showed significantly poorer overall and disease-free survival than PLS3-negative patients (P=0.0001 and 0.003, respectively). Subset analysis revealed that this prognostic biomarker was relevant in patients with stage I-III cancer, particularly in patients with luminal-type and triple-negative-type tumours.Conclusions:These data demonstrated that PLS3 was expressed in CTCs undergoing the epithelial-mesenchymal transition in patients with breast cancer. Furthermore, PLS3 may be an excellent biomarker for identifying groups at risk of recurrence or with a poor prognosis.

Original languageEnglish
Pages (from-to)1519-1526
Number of pages8
JournalBritish journal of cancer
Volume112
Issue number9
DOIs
Publication statusPublished - Apr 28 2015

Fingerprint

Circulating Neoplastic Cells
Breast Neoplasms
Biomarkers
Epithelial-Mesenchymal Transition
Cell Line
Neoplasms
Disease-Free Survival
Bone Marrow
Recurrence

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Circulating tumour cell-derived plastin3 is a novel marker for predicting long-term prognosis in patients with breast cancer. / Ueo, H.; Sugimachi, K.; Gorges, T. M.; Bartkowiak, K.; Yokobori, T.; Müller, V.; Shinden, Y.; Ueda, M.; Ueo, H.; Mori, M.; Kuwano, H.; Maehara, Y.; Ohno, S.; Pantel, K.; Mimori, K.

In: British journal of cancer, Vol. 112, No. 9, 28.04.2015, p. 1519-1526.

Research output: Contribution to journalArticle

Ueo, H, Sugimachi, K, Gorges, TM, Bartkowiak, K, Yokobori, T, Müller, V, Shinden, Y, Ueda, M, Ueo, H, Mori, M, Kuwano, H, Maehara, Y, Ohno, S, Pantel, K & Mimori, K 2015, 'Circulating tumour cell-derived plastin3 is a novel marker for predicting long-term prognosis in patients with breast cancer', British journal of cancer, vol. 112, no. 9, pp. 1519-1526. https://doi.org/10.1038/bjc.2015.132
Ueo, H. ; Sugimachi, K. ; Gorges, T. M. ; Bartkowiak, K. ; Yokobori, T. ; Müller, V. ; Shinden, Y. ; Ueda, M. ; Ueo, H. ; Mori, M. ; Kuwano, H. ; Maehara, Y. ; Ohno, S. ; Pantel, K. ; Mimori, K. / Circulating tumour cell-derived plastin3 is a novel marker for predicting long-term prognosis in patients with breast cancer. In: British journal of cancer. 2015 ; Vol. 112, No. 9. pp. 1519-1526.
@article{bd266f1a4a534ccebcd4f006c9be1137,
title = "Circulating tumour cell-derived plastin3 is a novel marker for predicting long-term prognosis in patients with breast cancer",
abstract = "Background:Identification of promising biomarkers that predict the prognosis of patients with breast cancer is needed. In this study, we hypothesised that the expression of the epithelial-mesenchymal transition-related biomarker plastin3 (PLS3) in peripheral blood could be a prognostic factor in breast cancer.Methods:We examined PLS3 expression in breast cancer cell lines with epithelial and mesenchymal traits and in circulating tumour cells (CTCs) obtained from the peripheral blood of breast cancer patients. We investigated PLS3 expression in the peripheral blood of 594 patients with breast cancer to evaluate the clinical significance of PLS3 expression.Results:Robust PLS3 expression was observed in different breast cancer cell lines (Hs578t, MCF-7, MDA-MB-468, and MDA-MB-231) as well as in a bone marrow derived cancer cell line (BC-M1). In both the training (n=298) and validation (n=296) sets, PLS3 expression was observed in CTCs of patients with breast cancer. PLS3-positive patients showed significantly poorer overall and disease-free survival than PLS3-negative patients (P=0.0001 and 0.003, respectively). Subset analysis revealed that this prognostic biomarker was relevant in patients with stage I-III cancer, particularly in patients with luminal-type and triple-negative-type tumours.Conclusions:These data demonstrated that PLS3 was expressed in CTCs undergoing the epithelial-mesenchymal transition in patients with breast cancer. Furthermore, PLS3 may be an excellent biomarker for identifying groups at risk of recurrence or with a poor prognosis.",
author = "H. Ueo and K. Sugimachi and Gorges, {T. M.} and K. Bartkowiak and T. Yokobori and V. M{\"u}ller and Y. Shinden and M. Ueda and H. Ueo and M. Mori and H. Kuwano and Y. Maehara and S. Ohno and K. Pantel and K. Mimori",
year = "2015",
month = "4",
day = "28",
doi = "10.1038/bjc.2015.132",
language = "English",
volume = "112",
pages = "1519--1526",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Circulating tumour cell-derived plastin3 is a novel marker for predicting long-term prognosis in patients with breast cancer

AU - Ueo, H.

AU - Sugimachi, K.

AU - Gorges, T. M.

AU - Bartkowiak, K.

AU - Yokobori, T.

AU - Müller, V.

AU - Shinden, Y.

AU - Ueda, M.

AU - Ueo, H.

AU - Mori, M.

AU - Kuwano, H.

AU - Maehara, Y.

AU - Ohno, S.

AU - Pantel, K.

AU - Mimori, K.

PY - 2015/4/28

Y1 - 2015/4/28

N2 - Background:Identification of promising biomarkers that predict the prognosis of patients with breast cancer is needed. In this study, we hypothesised that the expression of the epithelial-mesenchymal transition-related biomarker plastin3 (PLS3) in peripheral blood could be a prognostic factor in breast cancer.Methods:We examined PLS3 expression in breast cancer cell lines with epithelial and mesenchymal traits and in circulating tumour cells (CTCs) obtained from the peripheral blood of breast cancer patients. We investigated PLS3 expression in the peripheral blood of 594 patients with breast cancer to evaluate the clinical significance of PLS3 expression.Results:Robust PLS3 expression was observed in different breast cancer cell lines (Hs578t, MCF-7, MDA-MB-468, and MDA-MB-231) as well as in a bone marrow derived cancer cell line (BC-M1). In both the training (n=298) and validation (n=296) sets, PLS3 expression was observed in CTCs of patients with breast cancer. PLS3-positive patients showed significantly poorer overall and disease-free survival than PLS3-negative patients (P=0.0001 and 0.003, respectively). Subset analysis revealed that this prognostic biomarker was relevant in patients with stage I-III cancer, particularly in patients with luminal-type and triple-negative-type tumours.Conclusions:These data demonstrated that PLS3 was expressed in CTCs undergoing the epithelial-mesenchymal transition in patients with breast cancer. Furthermore, PLS3 may be an excellent biomarker for identifying groups at risk of recurrence or with a poor prognosis.

AB - Background:Identification of promising biomarkers that predict the prognosis of patients with breast cancer is needed. In this study, we hypothesised that the expression of the epithelial-mesenchymal transition-related biomarker plastin3 (PLS3) in peripheral blood could be a prognostic factor in breast cancer.Methods:We examined PLS3 expression in breast cancer cell lines with epithelial and mesenchymal traits and in circulating tumour cells (CTCs) obtained from the peripheral blood of breast cancer patients. We investigated PLS3 expression in the peripheral blood of 594 patients with breast cancer to evaluate the clinical significance of PLS3 expression.Results:Robust PLS3 expression was observed in different breast cancer cell lines (Hs578t, MCF-7, MDA-MB-468, and MDA-MB-231) as well as in a bone marrow derived cancer cell line (BC-M1). In both the training (n=298) and validation (n=296) sets, PLS3 expression was observed in CTCs of patients with breast cancer. PLS3-positive patients showed significantly poorer overall and disease-free survival than PLS3-negative patients (P=0.0001 and 0.003, respectively). Subset analysis revealed that this prognostic biomarker was relevant in patients with stage I-III cancer, particularly in patients with luminal-type and triple-negative-type tumours.Conclusions:These data demonstrated that PLS3 was expressed in CTCs undergoing the epithelial-mesenchymal transition in patients with breast cancer. Furthermore, PLS3 may be an excellent biomarker for identifying groups at risk of recurrence or with a poor prognosis.

UR - http://www.scopus.com/inward/record.url?scp=84928754958&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928754958&partnerID=8YFLogxK

U2 - 10.1038/bjc.2015.132

DO - 10.1038/bjc.2015.132

M3 - Article

C2 - 25880010

AN - SCOPUS:84928754958

VL - 112

SP - 1519

EP - 1526

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 9

ER -